SlideShare is now on Android. 15 million presentations at your fingertips.  Get the app

×
  • Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
 

Treating refractory hematological malignancies – myelodysplastic syndromes (mds) and acute myeloid leukemia (aml) emerging therapeutics - Reports Corner

by Working at Reports Corner on Sep 09, 2013

  • 206 views

The report provides an overview of the approved therapies for AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory pts. The report highlights the competition and ...

The report provides an overview of the approved therapies for AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory pts. The report highlights the competition and commercial opportunity in pursuing this therapy area – Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them.

https://www.reportscorner.com/reports/27493/Treating-Refractory-Hematological-Malignancies-%E2%80%93-Myelodysplastic-Syndromes-(MDS)-and-Acute-Myeloid-Leukemia-(AML):-Emerging-Therapeutics-/

Statistics

Views

Total Views
206
Views on SlideShare
206
Embed Views
0

Actions

Likes
0
Downloads
2
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via SlideShare as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
Post Comment
Edit your comment

Treating refractory hematological malignancies – myelodysplastic syndromes (mds) and acute myeloid leukemia (aml)   emerging therapeutics - Reports Corner Treating refractory hematological malignancies – myelodysplastic syndromes (mds) and acute myeloid leukemia (aml) emerging therapeutics - Reports Corner Presentation Transcript